Suven Life Sciences Limited, on Monday, has announced that it has got US patent for two new chemical entities (NCEs) for the treatment of neurological diseases.
In a statement to the BSE, the Hyderabad-based biopharmaceutical company said that U. S. patent office has approved two molecules in the central nervous system
(CNS) arena developed by the company for the treatment of cognitive disorders and these patents are applicable till 2022 and 2024.
The company also said that the patents included the class of selective 5-HT compounds developed by the company through its own research.
These compounds were being developed as therapeutic agents and will be used to cure cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder, Huntington's disease, Parkinson and Schizophrenia.
The company added that it now has four patents from US patent office on NCEs.